Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Total Assets
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd total assets. Based on the latest financial reports, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (688505) holds total assets worth CN¥2.39 Billion CNY (≈ $349.83 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Shanghai Fudan-Zhangjiang Bio-Pharmaceut worth for the company's overall valuation and market capitalisation.
Total Assets of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (2005–2025)
Total assets of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd from 2005 to 2025. This chart illustrates how Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. See 688505 live share price for real-time trading data and today's change.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd - Asset Composition Analysis
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Total Assets Breakdown (December 2025)
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd total assets breakdown as of December 2025. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's total assets of CN¥2.39 Billion consist of 62.1% current assets and 37.9% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 48.0% |
| Accounts Receivable | CN¥201.34 Million | 8.4% |
| Inventory | CN¥33.21 Million | 1.4% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥60.87 Million | 2.6% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2005–2025)
This chart illustrates how Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Shanghai Fudan-Zhangjiang Bio-Pharmaceut working capital to net assets to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's current assets represent 62.1% of total assets in 2025, an increase from 43.5% in 2005.
- Cash Position: Cash and equivalents constituted 48.0% of total assets in 2025, up from 34.8% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, unchanged from 2.0% in 2005.
- Asset Diversification: The largest asset category is accounts receivable at 8.4% of total assets.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Ajanta Pharma Limited
NSE:AJANTPHARM
|
India | Rs56.72 Billion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262
|
China | CN¥9.54 Billion |
|
Porton Fine Chemicals Ltd
SHE:300363
|
China | CN¥8.58 Billion |
|
Jubilant Pharmova Limited
NSE:JUBLPHARMA
|
India | Rs135.21 Billion |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.05 | 6.40 | 5.72 |
| Quick Ratio | 5.91 | 6.21 | 5.59 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.24 Billion | CN¥1.36 Billion | CN¥1.59 Billion |
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.92 |
| Latest Market Cap to Assets Ratio | 0.30 |
| Asset Growth Rate (YoY) | -7.6% |
| Total Assets | CN¥2.39 Billion |
| Market Capitalization | $728.33 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's assets below their book value (0.30x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd's assets decreased by 7.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (2005–2025)
The table below shows the annual total assets of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.39 Billion ≈ $349.83 Million |
-7.57% |
| 2024-12-31 | CN¥2.59 Billion ≈ $378.49 Million |
-10.09% |
| 2023-12-31 | CN¥2.88 Billion ≈ $420.95 Million |
-3.34% |
| 2022-12-31 | CN¥2.98 Billion ≈ $435.48 Million |
+7.01% |
| 2021-12-31 | CN¥2.78 Billion ≈ $406.97 Million |
+11.22% |
| 2020-12-31 | CN¥2.50 Billion ≈ $365.93 Million |
+59.81% |
| 2019-12-31 | CN¥1.56 Billion ≈ $228.98 Million |
+7.23% |
| 2018-12-31 | CN¥1.46 Billion ≈ $213.55 Million |
+27.44% |
| 2017-12-31 | CN¥1.15 Billion ≈ $167.57 Million |
+2.18% |
| 2016-12-31 | CN¥1.12 Billion ≈ $164.00 Million |
+9.85% |
| 2015-12-31 | CN¥1.02 Billion ≈ $149.30 Million |
+23.75% |
| 2014-12-31 | CN¥824.48 Million ≈ $120.65 Million |
+10.05% |
| 2013-12-31 | CN¥749.22 Million ≈ $109.63 Million |
+39.44% |
| 2012-12-31 | CN¥537.30 Million ≈ $78.62 Million |
+49.71% |
| 2011-12-31 | CN¥358.88 Million ≈ $52.52 Million |
+17.99% |
| 2010-12-31 | CN¥304.15 Million ≈ $44.51 Million |
+1.78% |
| 2009-12-31 | CN¥298.83 Million ≈ $43.73 Million |
+88.59% |
| 2008-12-31 | CN¥158.45 Million ≈ $23.19 Million |
+21.53% |
| 2007-12-31 | CN¥130.38 Million ≈ $19.08 Million |
-10.10% |
| 2006-12-31 | CN¥145.02 Million ≈ $21.22 Million |
+1.48% |
| 2005-12-31 | CN¥142.91 Million ≈ $20.91 Million |
-- |
About Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of biopharmaceutical products in the People's Republic of China. It offers photodynamic technology drugs, such as aminolevulinic acid hydrochloride and hemoporfin for Injection; doxorubicin liposome under the Libord brand; genetic engineering drugs; and oral solid preparation technol… Read more